<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657122</url>
  </required_header>
  <id_info>
    <org_study_id>0140</org_study_id>
    <nct_id>NCT02657122</nct_id>
  </id_info>
  <brief_title>SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects</brief_title>
  <official_title>A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma R &amp; D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma R &amp; D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of
      single ascending doses and multiple ascending doses of the investigational drug TD-1473
      compared to placebo in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of SAD and MAD of TD-1473 in healthy subjects by assessing the number, severity and type of adverse events, including changes in vital signs, physical examinations, laboratory safety tests and ECGs</measure>
    <time_frame>Day 1 through Day 8 (SAD) or 21 (MAD)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC) in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 4-6 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 4-6 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 4-6 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (t1/2) in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 4-6 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted in urine (Aeu)</measure>
    <time_frame>Day 1 through Day 4-6 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount excreted in feces (Aef)</measure>
    <time_frame>Day 1 through Day 4-6 (SAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 17-19 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 17-19 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 17-19 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 in plasma, urine and feces</measure>
    <time_frame>Day 1 through Day 17-19 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aeu</measure>
    <time_frame>Day 1 through Day 17-19 (MAD)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aef</measure>
    <time_frame>Day 1 through Day 17-19 (MAD)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TD-1473 for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 of out 8 subjects per cohort will be randomized to receive TD-1473</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 of out 8 subjects per cohort will be randomized to receive placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1473 for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 of out 8 subjects per cohort will be randomized to receive TD-1473</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 of out 8 subjects per cohort will be randomized to receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473 for SAD</intervention_name>
    <description>SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.</description>
    <arm_group_label>TD-1473 for SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for SAD</intervention_name>
    <description>SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.</description>
    <arm_group_label>Placebo for SAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473 for MAD</intervention_name>
    <description>MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.</description>
    <arm_group_label>TD-1473 for MAD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for MAD</intervention_name>
    <description>MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.</description>
    <arm_group_label>Placebo for MAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female 19 to 55 years old

          -  Willing and able to give informed consent

          -  Body Mass Index (BMI) 18 to 30 kg/m2

          -  Women of child bearing potential must have a negative pregnancy test and either
             abstain from sex or use a highly effective method of birth control

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  Positive for hepatitis A, B, or C, HIV, or tuberculosis (TB)

          -  Clinically significant abnormalities in baseline results of laboratory evaluations

          -  Evidence or history of clinically significant allergic (except for untreated,
             asymptomatic, seasonal allergies at time of dosing), hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological
             disease

          -  Participated in another clinical trial of an investigational drug (or medical device)
             within 30 days prior to Screening (or within 60 days prior to Screening if
             investigational drug was a biologic), or is currently participating in another trial
             of an investigational drug (or medical device)

          -  Use of prescription drugs or any chronic over the counter medications within 14 days
             prior to clinic admission or requires continuing use during study participation, with
             the exception of hormonal contraceptives or hormone replacement therapy.

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Graham, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma R &amp; D, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single ascending dose</keyword>
  <keyword>SAD</keyword>
  <keyword>multiple ascending dose</keyword>
  <keyword>MAD</keyword>
  <keyword>Phase 1</keyword>
  <keyword>first-in-human</keyword>
  <keyword>volunteers</keyword>
  <keyword>TD-1473</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

